Compare · AXGN vs MASI
AXGN vs MASI
Side-by-side comparison of Axogen Inc. (AXGN) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.31B, about 4.3x AXGN ($2.17B).
- Over the past year, AXGN is up 157.0% and MASI is up 11.0% - AXGN leads by 146.0 points.
- AXGN has been more active in the news (6 items in the past 4 weeks vs 4 for MASI).
- MASI has more recent analyst coverage (24 ratings vs 8 for AXGN).
- Company
- Axogen Inc.
- Masimo Corporation
- Price
- $41.79-0.38%
- $178.47-0.02%
- Market cap
- $2.17B
- $9.31B
- 1M return
- +33.39%
- +0.66%
- 1Y return
- +157.01%
- +10.99%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 6
- 4
- Recent ratings
- 8
- 24
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest AXGN
- SEC Form DEF 14A filed by Axogen Inc.
- SEC Form 10-Q filed by Axogen Inc.
- Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen, Inc. Reports First Quarter 2026 Financial Results
- CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
- Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Axogen Inc.
- SEC Form 4 filed by Devinney Erick Wayne
- SEC Form 4 filed by Hartley Lindsey Marie
- Chief Marketing Officer Kemp Jens was granted 50,670 shares and covered exercise/tax liability with 18,366 shares, increasing direct ownership by 73% to 76,451 units (SEC Form 4)
Latest MASI
- Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
- SEC Form DEFA14A filed by Masimo Corporation
- Masimo Corporation filed SEC Form 8-K: Other Events
- Telix Strengthens Board with Additional Director Appointments
- SEC Form DEFM14A filed by Masimo Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Masimo Corporation
- Masimo downgraded by Raymond James
- SEC Form PREM14A filed by Masimo Corporation
- CEO Szyman Catherine M. covered exercise/tax liability with 1,069 shares and converted options into 2,101 shares, increasing direct ownership by 16% to 7,605 units (SEC Form 4)
- EVP & Chief Financial Officer Young Micah W converted options into 873 shares and covered exercise/tax liability with 471 shares, increasing direct ownership by 2% to 25,656 units (SEC Form 4)